Expressions of vascular endothelial growth factor and nitric oxide synthase III in the thyroid gland of ovariectomized rats are upregulated by estrogen and selective estrogen receptor modulators

Thyroid

Volumn 20, Issue 1, 2010, Pages 85-92

  De Araujo, Luiz Felipe Bittencourt ^a   Grozovsky, Renata ^a   Dos Santos Pereira, Mário José ^b   De Carvalho, Jorge José ^b   Vaisman, Mário ^a   Carvalho, Denise P ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL BENZOATE; PROPYLENE GLYCOL; RALOXIFENE; TAMOXIFEN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; ESTROGEN ACTIVITY; FEMALE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; THYROID FOLLICLE CELL; THYROID GLAND; THYROID WEIGHT; UPREGULATION; VASCULARIZATION;

ACTINS; ANIMALS; ESTRADIOL; ESTROGENS; FEMALE; IMMUNOHISTOCHEMISTRY; MICROVESSELS; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; OVARIECTOMY; RALOXIFENE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; THYROID GLAND; UP-REGULATION; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 75149192579     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0246     Document Type: Article

References (66)

1. Simoncini T, Genazzani AR 2003 Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148:281-292.
2. Deroo BJ, Korach KS 2006 Estrogen receptors and human disease. J Clin Invest 116:561-570.
3. Rusnati M, Casarotti G, Pecorelli S, Ragnotti G, Presta M 1993 Estro-progestinic replacement therapy modulates the levels of basic fibroblast growth factor (bFGF) in postmenopausal endometrium. Gynecol Oncol 48:88-93.
4. Rubanyi GM, Johns A, Kauser K 2002 Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol 38: 89-98.
5. Losordo DW, Isner JM 2001 Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 21:6-12.
6. Hyder SM 2002 The role of steroid hormones on the regulation of vascular endothelial growth factor. Am J Pathol 161:345-346.
7. Greb RR, Heikinheimo O, Williams RF, Hodgen GD, Goodman AL 1997 Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum Reprod 12:1280-1292.
8. Van Buren GA, Yang DS, Clark KE 1992 Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol 167:828-833.
9. Rosenfeld CR, Cox BE, Roy T, Magness RR 1996 Nitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation. J Clin Invest 98:2158-2166.
10. White RE 2002 Estrogen and vascular function. Vascul Pharmacol 38:73-80.
11. Grese TA, Dodge JA 1998 Selective estrogen receptor modulators (SERMs). Curr Pharm Des 4:71-92.
12. Jordan VC 2001 Selective estrogen receptor modulation: a personal perspective. Cancer Res 61:5683-5687.
13. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467.
14. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15.
15. Bryant UH, Dere WH 1998 Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 217:45-52.
16. Vogel VG, Constantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP) 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741. (Pubitemid 43920726)
17. Mcdonnell DP 2000 Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen. J Soc Gynecol Investig 7(1 Suppl):S10-S15.
18. Park WC, Jordan VC 2002 Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med 8:82-88.
19. MacGregor JI, Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-196.
20. Black LJ, Jones CD, Falcone JF 1983 Antagonism of estrogen action with a new benzothiofene derived antiestrogen. Life Sci 32:1031-1036.
21. Khovidhunkit W, Shoback DM 1999 Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130:431-439.
22. Bagdade JD, Wolter J, Subbaiah PV, Ryan W 1990 Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 70:1132-1135.
23. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL 1991 Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864.
24. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856.
25. Rahimian R, Dubé GP, Toma W, Dos Santos N, McManus BM, van Breemen C 2002 Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 434:141-149.
26. Hutchison SJ, Chou TM, Chatterjee K, Sudhir K 2001 Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J Cardiovasc Pharmacol 38:657-665.
27. Figtree GA, Lu Y, Webb CM, Collins P 1999 Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100:1095-1101.
28. Cuzick J, Allen D, Baum M, Barret J, Clark G, Kakkar V, Melissiari E, Moniz C, Moore J, Parsons V, Pemberton P, Pitt P, Richmond W, Houghton J, Riley D 1993 Long term effects of tamoxifen. Eur J Cancer 29A:15-21.
29. Jordan VC, Murphy CS 1990 Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11:578-610.
30. Hanstein B, Djahansouzi S, Dall P, Beckmann MW, Bender HG 2004 Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol 150:243-255.
31. Chaudhuri PK, Patel N, Sandberg L, Prinz RA 1986 Distribution and characterization of steroid hormone receptors in human thyroid tissue. World J Surg 10:737-744.
32. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M 2001 Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 86:1072-1077.
33. Banu SK, Govindarajulu P, Aruldhas MM 2002 Testosterone and estradiol differentially regulate TSH-induced thyrocyte proliferation in immature and adult rats. Steroids 67:573-579.
34. Grosvenor CE 1962 Effects of estrogen upon thyroidal I-131 release and excretion of thyroxine in ovariectomized rats. Endocrinology 70:673-678.
35. Götze S, Nishino Y, Neumann F 1984 Anti-oestrogenic effects of tamoxifen on mammary gland and hypophysis in female rats. Acta Endocrinol 105:360-370.
36. Cyr M, Landry M, Di Paolo T 2000 Modulation by estrogenreceptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 23:69-78.
37. Lima LP, Barros IA, Lisbôa PC, Araú jo RL, Silva AC, Rosenthal D, Ferreira AC, Carvalho DP 2006 Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats. Steroids 71:653-659.
38. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69.
39. Sato M, Rippy MK, Bryant HU 1996 Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10:905-912. (Pubitemid 26184169)
40. Denef JF, Cordier AC, Mesquita M, Haumont S 1979 The influence of fixation procedure, embedding medium and section thickness on morphometric data in thyroid gland. Histochemistry 63:163-171.
41. Li W, Tanaka K, Chiba Y, Kimura T, Morioka K, Uesaka T, Ihaya A, Sasaki M, Tsuda T, Yamada N 2003 Role of MMPs and plasminogen activators in angiogenesis after transmyocardial laser revascularization in dogs. Am J Physiol Heart Circ Physiol 284:H23-H30.
42. Baum O, Djonov V, Ganster M, Widmer M, Baumgartner I 2005 Arteriolization of capillaries and FGF-2 upregulation in skeletal muscles of patients with chronic peripheral arterial disease. Microcirculation 12:527-537.
43. Wollman SH, Herveg JP, Zeligs JD, Ericson LE 1978 Blood capillary enlargement during the development of thyroid hyperplasia in the rat. Endocrinology 103:2306-2314.
44. Gérard AC, Many MC, Daumerie C, Costagliola S, Miot F, DeVijlder JJ, Colin IM, Denef JF 2002 Structural changes in the angiofollicular units between active and hypofunctioning follicles align with differences in the epithelial expression of newly discovered proteins involved in iodine transport and organification. J Clin Endocrinol Metab 87:1291-1299.
45. Denef JF, Ovaert C, Many MC 1989 Experimental goitrogenesis. Ann Endocrinol 50:1-15.
46. Gérard AC, Xhenseval V, Colin IM, Many MC, Denef JF 2000 Evidence for co-ordinated changes between vascular endothelial growth factor and nitric oxide synthase III immunoreactivity, the functional status of the thyroid follicles, and the microvascular bed during chronic stimulation by low iodine and propylthiouracyl in old mice. Eur J Endocrinol 142:651-660.
47. Dumont JE, Herveg JP, Tachiwaki O 1992 Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 72:667-697.
48. Hart JE 1990 Endocrine pathology of estrogens: species differences. Pharmacol Ther 47:203-218.
49. Al-Azzawi F 1992 Endocrinological aspects of the menopause. Br Med Bull 48:262-275.
50. Faggiano A, Coulot J, Bellon N, Talbot M, Caillou B, Ricard M, Bidart JM, Schlumberger M 2004 Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue. J Nucl Med 45:232-237.
51. Studer H, Forster R, Conti A, Kohler H, Haeberli A, Engler H 1978 Transformation of normal follicles into thyrotropinrefractory "cold" follicles in the aging mouse thyroid gland. Endocrinology 102:1576-1586.
52. de Araujo LF, Soares JM Jr, Simões RS, Calió PL, Oliveira-Filho RM, Simões Mde J, Haidar MA, Baracat EC 2006 Effect of conjugated equine estrogens and tamoxifen administration on thyroid gland histomorphology of the rat. Clinics 61:321-326.
53. Money SR, Muss W, Thelmo WL, Boeckl O, Pimpl W, Kaindl H, Sungler P, Kirwin J, Waclawicek H, Jaffe BM, Pertshuk LP 1989 Immunocytochemical localization of estrogen and progesterone receptors in human thyroid. Surgery 106:975-979.
54. Banu SK, Arosh JA, Govindarajulu P, Aruldhas MM 2001 Testosterone and estradiol differentially regulate thyroid growth in Wistar rats from immature to adult age. Endocr Res 27:447-463.
55. Banu SK, Govindarajulu P, Aruldhas MM 2002 Testosterone and estradiol up-regulate androgen and estrogen receptors in immature and adult rat thyroid glands in vivo. Steroids 67:1007-1014.
56. Furlanetto TW, Nguyen LQ, Jameson JL 1999 Estradiol increases proliferation and down-regulates the sodium=iodide symporter gene in FRTL-5 cells. Endocrinology 140:5705-5711.
57. Ferrara N, Houck K, Jakeman L, Leung DW 1992 Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18-32.
58. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH 1997 Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741-3747.
59. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ 1998 Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 157:5-12.
60. Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, Duh QY 1996 Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 120:944-947.
61. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG 1997 Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1=KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracilfed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15:2687-2698.
62. Miyagi E, Katoh R, Li X, Lu S, Suzuki K, Maeda S, Shibuya M, Kawaoi A 2001 Thyroid stimulating hormone downregulates vascular endothelial growth factor expression in FRTL-5 cells. Thyroid 11:539-543. (Pubitemid 32578710)
63. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR 1995 Vascular permeability factor=vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107:233-235.
64. Palade GE, Simionescu M, Simionescu N 1979 Structural aspects of the permeability of the microvascular endothelium. Acta Physiol Scand Suppl 463:11-32.
65. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N 1992 Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244-253.
66. Nathan C, Xie QW 1994 Nitric oxide synthases: roles, tolls, and controls. Cell 78:915-918.